Found 54 Breast Cancer trials
A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A study evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.
Supplement Screening for Breast Cancer with Abbreviated MRI for Black Women with Increased Breast Density
It is well known that black women develop breast cancers which present not only at an earlier age when breasts are denser, but also the cancers tend to be more aggressive subtypes than those found in Caucasian women of a similar age. In addition, the population-based breast cancer mortality for …
EVALUATING THE UPTAKE OF [18F] FLUOROESTRADIOL (FES) BPET/DBT IN PRIMARY BREAST CANCER TO MEASURE THE LOCALIZED EXTENT OF ESTROGEN RECEPTOR POSITIVE DISEASE
The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast …
PILOT STUDY EVALUATING THE UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER
This is a pilot study in patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to …
A Randomized Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+) HER2 (-) Breast Cancer
The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible …
Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
This study is being done to evaluate if participants with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy and two HER-targeting therapies eliminate further chemotherapy after surgery. Eligible subjects would be those with HER2-positive breast cancer.
A Randomized Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines
You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart …
FES PET/CT in Endocrine Refractory Breast Cancer
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study. Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …
UPCC 03121: AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
The purpose of this research is to increase the understanding of tumor spread and treatment benefit in the setting of metastatic breast cancer. Study participation involves the collection of tissue and blood specimens for use in breast cancer research.
A Phase 1/2 Study of Oral LOXO-292 in Patients
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
Please choose between Voice or SMS based delivery of verification code
or